Application progress of Evans blue modified radiopharmaceuticals for theranostics

VernacularTitle:伊文思蓝改构放射性药物在诊疗一体化中的应用进展
Author: Guochang WANG ¹ ; Pengfei XU ; Jingjing ZHANG ; Xiaoyuan CHEN
Author Information

1. 中国医学科学院、北京协和医学院北京协和医院核医学科、疑难重症及罕见病国家重点实验室、核医学分子靶向诊疗北京市重点实验室，北京　100730
Keywords: Precision medicine; Radiopharmaceuticals; Evans blue; Trends
From: Chinese Journal of Nuclear Medicine and Molecular Imaging 2024;44(1):35-40
CountryChina
Language:Chinese
Abstract: Theranostics in nuclear medicine is an important direction for the precision medicine. Radionuclide therapy based on small molecules/peptides often requires high doses. Improving the utilization efficiency of radionuclides, optimizing the pharmacokinetics of radionuclide therapeutic molecular probes as well as increasing the target to non-target ratio have become the international hot frontiers in the field of radiotheranostics. Evans blue (EB) motif uses endogenous albumin as a reversible carrier, and the small molecule and polypeptide structure modified based on EB can effectively extend the half-life in the blood and substantially increase the uptake, accumulation and retention of radiopharmaceuticals in target lesions, and thereby enhance the therapeutic effect and reduce the dosage of nuclides. This article focuses on the research of EB modified radiopharmaceuticals for theranostics.